| 0 (0%) | 04-19 10:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.13 | 1-year : | 11.99 |
| Resists | First : | 9.53 | Second : | 10.27 |
| Pivot price | 8.99  |
|||
| Supports | First : | 8.35 | Second : | 6.94 |
| MAs | MA(5) : | 8.52 |
MA(20) : | 8.97 |
| MA(100) : | 9.19 |
MA(250) : | 10.81 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14  |
D(3) : | 10.8 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 14.82 | Low : | 8.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GAMB ] has closed above bottom band by 18.0%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.67 - 8.7 | 8.7 - 8.74 |
| Low: | 8.44 - 8.47 | 8.47 - 8.52 |
| Close: | 8.53 - 8.59 | 8.59 - 8.66 |
Fri, 15 Dec 2023
Agomab Therapeutics doses first subject in Phase I IPF drug trial - Clinical Trials Arena
Thu, 14 Dec 2023
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis - Business Wire
Sat, 18 Nov 2023
AG Mortgage Bank Adopts Innovative Home Ownership Drive - THISDAY Newspapers
Wed, 11 Oct 2023
Agomab Therapeutics NV raises US$100m in Series C financing - European Biotechnology News
Wed, 11 Oct 2023
Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how - Silicon Canals
Wed, 11 Oct 2023
Agomab adds $100M in series C funds to push ALK5 inhibitor through phase 2 Crohn's trial - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 37 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 46 (%) |
| Held by Institutions | 43.6 (%) |
| Shares Short | 267 (K) |
| Shares Short P.Month | 288 (K) |
| EPS | 0.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.19 |
| Profit Margin | 16.8 % |
| Operating Margin | 27.2 % |
| Return on Assets (ttm) | 12.6 % |
| Return on Equity (ttm) | 17.7 % |
| Qtrly Rev. Growth | 52.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.91 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 18 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | 18.1 |
| PEG Ratio | 0 |
| Price to Book value | 2.66 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 17.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|